Last reviewed · How we verify
BioFarma Bivalent Oral Poliomyelitis Vaccine
BioFarma Bivalent Oral Poliomyelitis Vaccine is a Live attenuated viral vaccine Biologic drug developed by PATH. It is currently in Phase 3 development for Prevention of poliomyelitis caused by poliovirus types 1 and 3.
This bivalent oral polio vaccine stimulates mucosal and systemic immune responses against poliovirus types 1 and 3 to prevent poliomyelitis infection.
This bivalent oral polio vaccine stimulates mucosal and systemic immune responses against poliovirus types 1 and 3 to prevent poliomyelitis infection. Used for Prevention of poliomyelitis caused by poliovirus types 1 and 3.
At a glance
| Generic name | BioFarma Bivalent Oral Poliomyelitis Vaccine |
|---|---|
| Sponsor | PATH |
| Drug class | Live attenuated viral vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains live attenuated poliovirus strains (types 1 and 3) administered orally, which replicate in the intestinal mucosa and induce both local secretory IgA antibodies and systemic IgG responses. This dual immune response provides protection against infection and transmission of the targeted poliovirus serotypes. The oral route allows for convenient mass vaccination campaigns, particularly in resource-limited settings.
Approved indications
- Prevention of poliomyelitis caused by poliovirus types 1 and 3
Common side effects
- Mild gastrointestinal symptoms
- Fever
- Local or systemic reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BioFarma Bivalent Oral Poliomyelitis Vaccine CI brief — competitive landscape report
- BioFarma Bivalent Oral Poliomyelitis Vaccine updates RSS · CI watch RSS
- PATH portfolio CI
Frequently asked questions about BioFarma Bivalent Oral Poliomyelitis Vaccine
What is BioFarma Bivalent Oral Poliomyelitis Vaccine?
How does BioFarma Bivalent Oral Poliomyelitis Vaccine work?
What is BioFarma Bivalent Oral Poliomyelitis Vaccine used for?
Who makes BioFarma Bivalent Oral Poliomyelitis Vaccine?
What drug class is BioFarma Bivalent Oral Poliomyelitis Vaccine in?
What development phase is BioFarma Bivalent Oral Poliomyelitis Vaccine in?
What are the side effects of BioFarma Bivalent Oral Poliomyelitis Vaccine?
Related
- Drug class: All Live attenuated viral vaccine drugs
- Manufacturer: PATH — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of poliomyelitis caused by poliovirus types 1 and 3
- Compare: BioFarma Bivalent Oral Poliomyelitis Vaccine vs similar drugs
- Pricing: BioFarma Bivalent Oral Poliomyelitis Vaccine cost, discount & access